Get the Stockscreener App
4.97
0.00%
0.01
Atea Pharmaceuticals Inc stock is traded at $4.97, with a volume of 192.04K.
It is up +0.00% in the last 24 hours and up +17.18% over the past month.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
See More
Previous Close:
$4.98
Open:
$4.94
24h Volume:
192.04K
Relative Volume:
0.58
Market Cap:
$397.33M
Revenue:
$351.37M
Net Income/Loss:
$-169.52M
P/E Ratio:
-2.3403
EPS:
-2.1237
Net Cash Flow:
$-147.86M
1W Performance:
+8.03%
1M Performance:
+17.18%
6M Performance:
+46.04%
1Y Performance:
+33.16%
1-Day Range:
$4.7707
$5.03
1-Week Range:
$4.55
$5.035
52-Week Range:
$2.78
$6.45
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
(857) 284-8891
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
4.965 | 372.13M | 351.37M | -169.52M | -147.86M | -2.1237 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to sales forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Refocuses Antiviral Pipeline - Kalkine Media
Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR) - TradingView
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVIR Forecast — Price Target — Prediction for 2027 - TradingView
Atea completes enrollment in phase 3 hepatitis C trial By Investing.com - Investing.com Australia
Atea completes enrollment in phase 3 hepatitis C trial - Investing.com UK
Atea Pharmaceuticals Completes Patient Enrollment in Phase - GlobeNewswire
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Nigeria
Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs - Stock Titan
[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Equity awards boost Atea (AVIR) director Barbara Duncan’s holdings - Stock Titan
Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR) - Stock Titan
Atea Pharmaceuticals (AVIR) director receives new options and RSU awards - Stock Titan
Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director - Stock Titan
Atea Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Nigeria
Atea Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa
Atea Pharmaceuticals (NASDAQ: AVIR) reports 2026 annual meeting and vote outcomes - Stock Titan
Atea Pharmaceuticals (AVIR) upgraded to buy: Here's what you should know - MSN
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Institutional Confidence - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16 - MSN
Atea Pharmaceuticals (AVIR) Slides 3.79%: Testing Key Support Near $4.10 Amid Ongoing VolatilitySchiff Line - dars.gov.et
Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year? - MSN
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Atea Pharmaceuticals (AVIR) Rallies 1.65% as Shares Test Key Resistance Near $4.54Scalping Stock Signals - newsline.com
Atea Pharmaceuticals (AVIR) Declines 3.85% as Shares Approach Key Support LevelPCR Mean Reversion - newsline.com
AVIR Stock Chart | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
536,097 |
| DUNCAN BARBARA GAYLE | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Polsky Bruce | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
124,806 |
| Murphy Polly A. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
121,745 |
| Adams Jerome M. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
29,600 |
0 |
92,350 |
| Corcoran Andrea | See Remarks |
Mar 11 '26 |
Option Exercise |
1.24 |
60,000 |
74,400 |
823,576 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman |
Feb 03 '26 |
Option Exercise |
1.24 |
300,000 |
372,000 |
767,830 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):